BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1185 related articles for article (PubMed ID: 34484235)

  • 1. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 4. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
    Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
    Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
    [No Abstract]   [Full Text] [Related]  

  • 6.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
    BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
    Mo Z; Liu D; Rong D; Zhang S
    Front Immunol; 2021; 12():611058. PubMed ID: 33679749
    [No Abstract]   [Full Text] [Related]  

  • 13. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
    Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 4-gene-based hypoxia signature is associated with tumor immune microenvironment and predicts the prognosis of pancreatic cancer patients.
    Ding J; He X; Cheng X; Cao G; Chen B; Chen S; Xiong M
    World J Surg Oncol; 2021 Apr; 19(1):123. PubMed ID: 33865399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 17. An EMT-based risk score thoroughly predicts the clinical prognosis, tumor immune microenvironment and molecular subtypes of bladder cancer.
    Xiao Z; Cai Z; Deng D; Tong S; Zu X
    Front Immunol; 2022; 13():1000321. PubMed ID: 36211349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
    Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
    Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
    Front Immunol; 2022; 13():898493. PubMed ID: 35812369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.